Resistance to high-maintenance dose of prasugrel treated by ticagrelor: a case report.
We describe a case of a 34-year-old woman with chronic renal failure under haemodialysis. The patient exhibited high on-treatment platelet reactivity to gradually stronger thienopyridine regimens, including standard and high maintenance doses of prasugrel. Platelet function was monitored by VerifyNow assay and genotyping for various single-nucleotide polymorphisms was performed. Treatment with ticagrelor 180 mg/day was effective in reducing the platelet reactivity.
Cardiology Department, University Hospital of Patras, Patras, Greece.
Ioanna
I
Xanthopoulou
Eleana F
EF
Stavrou
George
G
Kassimis
Pavlos
P
Goudas
Dimitrios
D
Alexopoulos
D000241:Adenosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D004351:Drug Resistance / Q000235:genetics; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D015539:Platelet Activation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000068799:Prasugrel Hydrochloride; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use; D058470:Receptors, Purinergic P2Y / Q000235:genetics; D006435:Renal Dialysis; D013876:Thiophenes / Q000008:administration & dosage / Q000627:therapeutic use*; D000077486:Ticagrelor
D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D058470:Receptors, Purinergic P2Y; D013876:Thiophenes; D000068799:Prasugrel Hydrochloride; D000077486:Ticagrelor; D000241:Adenosine